{
  "scenario_id": "healthcare_biotechnology_gene_therapy_investment_2025",
  "context": "Biotechnology company developing gene therapies for rare genetic disorders, seeking FDA approval",
  "stakeholders": {
    "requester": "Chief Scientific Officer",
    "approvers": ["CEO", "Board of Directors", "Chief Financial Officer"],
    "influencers": ["Clinical Development Director", "Regulatory Affairs Head", "Patient Advocacy Groups"]
  },
  "request": {
    "amount": "$120,000,000",
    "purpose": "Complete Phase 3 clinical trials and BLA submission for gene therapy treatment",
    "urgency": "high",
    "justification": "Address unmet medical need for patients with rare genetic disorders"
  },
  "decision_process": [
    {
      "stage": "scientific_review",
      "duration": "4 weeks",
      "activities": ["Preclinical data review", "Clinical trial design assessment", "Regulatory strategy evaluation"],
      "outcome": "Strong scientific rationale confirmed"
    },
    {
      "stage": "clinical_feasibility",
      "duration": "6 weeks",
      "activities": ["Patient recruitment analysis", "Clinical endpoint validation", "Safety profile assessment"],
      "outcome": "Feasible clinical development plan established"
    },
    {
      "stage": "financial_modeling",
      "duration": "3 weeks",
      "activities": ["Cost projections", "Revenue forecasting", "Risk-adjusted NPV analysis"],
      "outcome": "Approved with $95,000,000 investment and milestone-based funding"
    }
  ],
  "business_impact": {
    "expected_outcomes": ["FDA approval for gene therapy", "Market access for rare disease treatment", "Strategic partnerships with healthcare providers"],
    "projected_roi": "Potential blockbuster drug status with $500M+ annual revenue",
    "risk_factors": ["Clinical trial failures", "Regulatory approval delays", "Manufacturing scalability challenges", "Reimbursement negotiations"]
  }
}